Terremoto Biosciences: Series CDevelops highly targeted, small molecule medicines for cancer and rare diseasesOct 4, 2026RoundOSTerremoto BiosciencesCompany profile and funding historySourcesbusinesswire.comMore in BiotechAusperBio · Series CProFound Therapeutics · StrategicTransfyr · SeedBiotechUnited StatesNorth AmericaSeries C+